Stocks and Investing
Stocks and Investing
Tue, June 4, 2024
[ Tue, Jun 04th 2024
] - WOPRAI
[ Tue, Jun 04th 2024
] - WOPRAI
[ Tue, Jun 04th 2024
] - WOPRAI
[ Tue, Jun 04th 2024
] - WOPRAI
[ Tue, Jun 04th 2024
] - WOPRAI
[ Tue, Jun 04th 2024
] - WOPRAI
Mon, June 3, 2024
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
[ Mon, Jun 03rd 2024
] - WOPRAI
Tejas Savant Maintained (AKYA) at Buy with Decreased Target to $4 on, Jun 3rd, 2024
Tejas Savant of Morgan Stanley, Maintained "Akoya Biosciences, Inc." (AKYA) at Buy with Decreased Target from $8 to $4 on, Jun 3rd, 2024.
Tejas has made no other calls on AKYA in the last 4 months.
There are 4 other peers that have a rating on AKYA. Out of the 4 peers that are also analyzing AKYA, 0 agree with Tejas's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Tejas
- Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $6 on, Tuesday, May 14th, 2024
- Mark Massaro of "BTIG" Maintained at Strong Buy with Decreased Target to $6 on, Tuesday, May 14th, 2024
- Rachel Vatnsdal of "JP Morgan" Maintained at Buy with Decreased Target to $10 on, Wednesday, March 6th, 2024
- John Sourbeer of "UBS" Maintained at Strong Buy with Increased Target to $7.5 on, Tuesday, March 5th, 2024
Contributing Sources